- Fiscal 2022 SaaS revenue up 53% vs fiscal 2021
- Total contract value of fiscal 2022 SaaS bookings was $22.4 million compared to $5.6 million in fiscal 2021
- Reported $17.2 million of Booked SaaS ACV as of January 31, 2023, compared to $10.6 million as of January 31, 2022
- Executed strategic alignment of eValuator and Avelead operations
Atlanta, GA, April 26, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fourth quarter and fiscal year 2022, which ended January 31, 2023.
Fiscal Fourth Quarter and Full Year 2022 Financial Results
The following financial results have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”). Fiscal 2022 financial results reflect the consolidation of the Company with Avelead Consulting, LLC (“Avelead”), which was acquired in the fiscal third quarter of 2021. Fiscal 2021 GAAP financial results reflect results from Avelead’s operations from the date of acquisition, August 16, 2021.
Total revenues for the fourth quarter of fiscal 2022 were $6.7 million, a 12% increase from $6.0 million during the fourth quarter of fiscal 2021. Fiscal year 2022 revenues were $24.9 million, a 43% increase compared to $17.4 million during fiscal year 2021. The increase in revenue for the quarter was the result of higher SaaS revenue due to increased eValuator client volumes, higher software license revenue and increased professional services revenue from the Avelead business. The increase in revenue for the fiscal year was the result of higher SaaS and professional services revenue primarily attributable to the Avelead acquisition.
The Company is focused on the growth of its SaaS solutions. During the fourth quarter of fiscal 2022, SaaS revenue grew $0.4 million or 15% compared to the fourth quarter of fiscal 2021 and $4.2 million or 53% during the fiscal year ended January 31, 2023, compared to the prior fiscal year.
Net loss for the fourth quarter of fiscal 2022 was ($2.2) million as compared to a net loss of ($30,000) during the fourth quarter of fiscal 2021. Net loss for the fourth quarter of fiscal 2021 included income of $2.3 million related to a positive valuation adjustment arising from the acquisition of Avelead.
Net loss for fiscal 2022 was ($11.4) million, as compared to a net loss of ($6.5) million for fiscal 2021. The net loss for fiscal 2022 was impacted by higher overall operating expenses primarily as a result of having a full year in fiscal 2022 with Avelead operations as compared to a partial year in fiscal 2021. Fiscal 2021 net loss included $2.3 million of income related to PPP loan forgiveness and $1.9 million of income related to valuation adjustments arising from the Avelead acquisition.
Full Year 2022 Pro Forma and Non-GAAP Metrics
The following financial results for Fiscal 2021 are pro forma and have not been prepared in accordance with GAAP. These pro forma financial results represent the consolidation of the Company with Avelead as if Avelead’s operations were fully recognized during the comparable period.
Consolidated revenue for fiscal 2022 was $24.9 million, a 10% increase compared to pro forma, unaudited, consolidated revenue for fiscal 2021 of approximately $22.6 million. SaaS Revenue for fiscal 2022 was approximately $12.3 million, up 9% compared to $11.3 million of pro forma consolidated SaaS Revenue in fiscal 2021.
Adjusted EBITDA for the fourth quarter of fiscal 2022 was a loss of ($0.2) million, compared to an adjusted EBITDA loss of ($0.3) million in the fourth quarter of fiscal 2021. Adjusted EBITDA for the fiscal year ended January 31, 2023, was a loss of ($3.8) million as compared to an adjusted EBITDA loss of ($2.0) million during fiscal 2021.
As of January 31, 2023, the Company’s total Booked SaaS Annual Contract Value (“ACV”) was $17.2 million compared to Booked SaaS ACV of $10.6 million as of January 31, 2022. The company reiterated its expectation to exit fiscal 2023 with $30 million of Booked SaaS ACV. Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal.
Management Commentary
“We were pleased to achieve our bookings targets in fiscal 2022 and believe the strategic alignment we undertook in the fourth quarter will enable to us to maintain this level of execution going forward,” stated Tee Green, Chief Executive Officer, Streamline Health. “Our industry is adjusting to a new normal, and we believe that our solutions can play a major role in ensuring our healthcare providers are accurately paid for all of the care they’ve provided.”
Conference Call
The Company will conduct a conference call on Thursday, April 27, 2023, at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.
A replay of the conference call will be available from Thursday, April 27, 2023, at 12:00 PM ET to Thursday, May 4, 2023, at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13738301. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.
Non-GAAP Financial Measures
Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.
Streamline defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, share-based compensation expense, non-cash valuation adjustments, gains and losses on early extinguishments of debt, significant non-recurring operating expenses, and transactional related expenses including: associate severances and related restructuring expenses, transaction-related bonuses, associate inducements, and professional and advisory fees. A table reconciling this measure to “loss from continuing operations” is included in this press release.
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal. Booked SaaS ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. Booked SaaS ACV is not intended to be a replacement for, or forecast of, revenue. There is no GAAP measure comparable to Booked SaaS ACV.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, estimates of anticipated cash flow generation, anticipated bookings, recognition of revenue from contracts included in Booked SaaS ACV, industry trends and market growth, results of investments in sales and marketing, adjusted EBITDA, pro forma financial information, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog and Booked SaaS ACV, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Company Contact
Jacob Goldberger
Director, Investor Relations and FP&A
303-887-9625
Jacob.goldberger@streamlinehealth.net
STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(rounded to the nearest thousand dollars, except share and per share information)
| Three Months Ended January 31 | Twelve Months Ended January 31 | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenues: | ||||||||||||||||
| Software as a service | $ | 3,169,000 | $ | 2,767,000 | $ | 12,326,000 | $ | 8,077,000 | ||||||||
| Maintenance and support | 1,135,000 | 1,097,000 | 4,483,000 | 4,323,000 | ||||||||||||
| Professional fees and licenses | 2,441,000 | 2,182,000 | 8,080,000 | 4,979,000 | ||||||||||||
| Total revenues | 6,745,000 | 6,046,000 | 24,889,000 | 17,379,000 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of software as a service | 1,587,000 | 1,141,000 | 6,358,000 | 3,417,000 | ||||||||||||
| Cost of maintenance and support | 207,000 | 111,000 | 427,000 | 334,000 | ||||||||||||
| Cost of professional fees and licenses | 1,618,000 | 1,829,000 | 6,610,000 | 4,826,000 | ||||||||||||
| Selling, general and administrative expense | 3,646,000 | 3,424,000 | 16,134,000 | 11,931,000 | ||||||||||||
| Research and development | 1,515,000 | 1,502,000 | 6,042,000 | 4,782,000 | ||||||||||||
| Acquisition-related costs | 8,000 | 146,000 | 149,000 | 2,856,000 | ||||||||||||
| Total operating expenses | 8,581,000 | 8,153,000 | 35,720,000 | 28,146,000 | ||||||||||||
| Operating loss | (1,836,000 | ) | (2,107,000 | ) | (10,831,000 | ) | (10,767,000 | ) | ||||||||
| Other expense: | ||||||||||||||||
| Interest expense | (230,000 | ) | (129,000 | ) | (749,000 | ) | (236,000 | ) | ||||||||
| Loss on early extinguishment of debt | — | — | — | (43,000 | ) | |||||||||||
| Acquisition earnout valuation adjustments | (117,000 | ) | 2,268,000 | 71,000 | 1,851,000 | |||||||||||
| Other | 50,000 | 64,000 | 201,000 | 60,000 | ||||||||||||
| PPP loan forgiveness | — | — | — | 2,327,000 | ||||||||||||
| Income/(Loss) from continuing operations before income taxes | (2,133,000 | ) | 96,000 | (11,308,000 | ) | (6,808,000 | ) | |||||||||
| Income tax expense | (49,000 | ) | (100,000 | ) | (71,000 | ) | (109,000 | ) | ||||||||
| Loss from continuing operations | (2,182,000 | ) | (4,000 | ) | (11,379,000 | ) | (6,917,000 | ) | ||||||||
| Income from discontinued operations: | ||||||||||||||||
| Income from discontinued operations | — | — | — | 401,000 | ||||||||||||
| Income tax expense | — | (26,000 | ) | — | (26,000 | ) | ||||||||||
| Income from discontinued operations, net of tax | — | (26,000 | ) | — | 375,000 | |||||||||||
| Net loss | $ | (2,182,000 | ) | $ | (30,000 | ) | $ | (11,379,000 | ) | $ | (6,542,000 | ) | ||||
| Basic Earnings Per Share: | ||||||||||||||||
| Continuing operations | $ | (0.04 | ) | $ | (0.00 | ) | $ | (0.23 | ) | $ | (0.16 | ) | ||||
| Discontinued operations | — | (0.00 | ) | — | 0.01 | |||||||||||
| Net loss | $ | (0.04 | ) | $ | (0.00 | ) | $ | (0.23 | ) | $ | (0.15 | ) | ||||
| Weighted average number of common shares – basic | 55,309,665 | 46,764,335 | 49,324,858 | 42,815,239 | ||||||||||||
| Diluted Earnings Per Share: | ||||||||||||||||
| Continuing operations | $ | (0.04 | ) | $ | (0.00 | ) | $ | (0.23 | ) | $ | (0.16 | ) | ||||
| Discontinued operations | — | (0.00 | ) | — | 0.01 | |||||||||||
| Net loss per common share – diluted | $ | (0.04 | ) | $ | (0.00 | ) | $ | (0.23 | ) | $ | (0.15 | ) | ||||
| Weighted average number of common shares - diluted | 55,309,665 | 46,764,335 | 49,324,858 | 43,273,574 | ||||||||||||
STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(rounded to the nearest thousand dollars, except share and per share information)
| January 31, | ||||||||
| 2023 | 2022 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 6,598,000 | $ | 9,885,000 | ||||
| Accounts receivable, net of allowance for doubtful accounts of $132,000 and $76,000, respectively | 7,719,000 | 3,823,000 | ||||||
| Contract receivables | 960,000 | 843,000 | ||||||
| Prepaid and other current assets | 710,000 | 568,000 | ||||||
| Total current assets | 15,987,000 | 15,119,000 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net of accumulated amortization of $246,000 and $192,000 respectively | 79,000 | 123,000 | ||||||
| Right-of use asset for operating lease | 32,000 | 218,000 | ||||||
| Capitalized software development costs, net of accumulated amortization of $6,224,000 and $5,202,000, respectively | 5,846,000 | 5,555,000 | ||||||
| Intangible assets, net of accumulated amortization of $2,627,000 and $5,121,000, respectively | 14,793,000 | 16,763,000 | ||||||
| Goodwill | 23,089,000 | 23,089,000 | ||||||
| Other | 1,695,000 | 948,000 | ||||||
| Total non-current assets | 45,534,000 | 46,696,000 | ||||||
| Total assets | $ | 61,521,000 | $ | 61,815,000 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 626,000 | $ | 778,000 | ||||
| Accrued expenses | 3,265,000 | 1,803,000 | ||||||
| Current portion of term loan, net of deferred financing costs | 750,000 | 250,000 | ||||||
| Deferred revenues | 8,361,000 | 5,794,000 | ||||||
| Current portion of operating lease obligation | 35,000 | 204,000 | ||||||
| Current portion of acquisition earnout liability | 3,738,000 | 4,672,000 | ||||||
| Total current liabilities | 16,775,000 | 13,501,000 | ||||||
| Non-current liabilities: | ||||||||
| Term loan, net of current portion and deferred financing costs | 8,964,000 | 9,654,000 | ||||||
| Deferred revenues, less current portion | 167,000 | 136,000 | ||||||
| Operating lease obligations, less current portion | — | 33,000 | ||||||
| Acquisition earnout liability, less current portion | — | 4,161,000 | ||||||
| Other non-current liabilities | 104,000 | 286,000 | ||||||
| Total non-current liabilities | 9,235,000 | 14,270,000 | ||||||
| Total liabilities | 26,010,000 | 27,771,000 | ||||||
| Commitments and contingencies: | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, $0.01 par value per share, 85,000,000 and 65,000,000 shares authorized, respectively; 57,567,210 and 47,840,950 shares issued and outstanding, respectively | 576,000 | 478,000 | ||||||
| Additional paid in capital | 131,973,000 | 119,225,000 | ||||||
| Accumulated deficit | (97,038,000 | ) | (85,659,000 | ) | ||||
| Total stockholders’ equity | 35,511,000 | 34,044,000 | ||||||
| Total liabilities and stockholders’ equity | $ | 61,521,000 | $ | 61,815,000 | ||||
STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(rounded to the nearest thousand dollars)
| Fiscal Year | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (11,379,000 | ) | $ | (6,542,000 | ) | ||
| LESS: Income from discontinued operations, net of tax | — | (375,000 | ) | |||||
| Loss from continuing operations, net of tax | (11,379,000 | ) | (6,917,000 | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 4,313,000 | 3,697,000 | ||||||
| Acquisition earnout valuation adjustments | (71,000 | ) | (1,851,000 | ) | ||||
| Loss on early extinguishment of debt | — | 43,000 | ||||||
| Provision for deferred income taxes | 9,000 | 95,000 | ||||||
| Share-based compensation expense | 1,680,000 | 2,216,000 | ||||||
| Provision for accounts receivable allowance | 189,000 | 11,000 | ||||||
| Forgiveness of PPP loan | — | (2,327,000 | ) | |||||
| Changes in assets and liabilities: | ||||||||
| Accounts and contract receivables | (4,202,000 | ) | (129,000 | ) | ||||
| Other assets | (1,197,000 | ) | (346,000 | ) | ||||
| Accounts payable | (152,000 | ) | 17,000 | |||||
| Accrued expenses and other liabilities | 1,069,000 | 533,000 | ||||||
| Deferred revenues | 2,598,000 | 1,074,000 | ||||||
| Net cash used in operating activities – continuing operations | (7,143,000 | ) | (3,884,000 | ) | ||||
| Net cash provided by operating activities – discontinued operations | — | 380,000 | ||||||
| Cash flows from investing activities: | ||||||||
| Investment in Avelead, net of cash acquired | — | (12,470,000 | ) | |||||
| Purchases of property and equipment | (10,000 | ) | (41,000 | ) | ||||
| Proceeds from sale of ECM Assets | — | 800,000 | ||||||
| Capitalization of software development costs | (1,925,000 | ) | (1,458,000 | ) | ||||
| Net cash used in investing activities – continuing operations | (1,935,000 | ) | (13,169,000 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of common stock | 8,316,000 | 16,100,000 | ||||||
| Payment of acquisition earnout liabilities | (2,012,000 | ) | — | |||||
| Payments for costs directly attributable to the issuance of common stock | (52,000 | ) | (1,313,000 | ) | ||||
| Repayment of bank term loan | (250,000 | ) | — | |||||
| Proceeds from term loan payable | — | 10,000,000 | ||||||
| Payments related to settlement of employee shared-based awards | (197,000 | ) | (464,000 | ) | ||||
| Payment of deferred financing costs | (20,000 | ) | (168,000 | ) | ||||
| Other | 6,000 | (6,000 | ) | |||||
| Net cash provided by financing activities – continuing operations | 5,791,000 | 24,149,000 | ||||||
| Net (decrease) increase in cash and cash equivalents | (3,287,000 | ) | 7,476,000 | |||||
| Cash and cash equivalents at beginning of period | 9,885,000 | 2,409,000 | ||||||
| Cash and cash equivalents at end of period | $ | 6,598,000 | $ | 9,885,000 | ||||
| Supplemental cash flow disclosures: | ||||||||
| Interest paid, net of amounts capitalized | $ | 651,000 | $ | 153,000 | ||||
| Income taxes paid | $ | 23,000 | $ | 21,000 | ||||
STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
NEW BOOKINGS
(rounded to the nearest thousand dollars)
| January 31, 2023 | ||||||||
| Three Months Ended | Twelve Months Ended | |||||||
| Software as a service | 8,325,000 | 22,447,000 | ||||||
| Maintenance and support | 656,000 | 712,000 | ||||||
| Professional fees and licenses | 1,595,000 | 3,303,000 | ||||||
| Q4 2022 Bookings | $ | 10,576,000 | 26,462,000 | |||||
| Q4 2021 Bookings | $ | 7,053,966 | 13,253,236 | |||||
*Bookings are presented on a total contract value basis, and include Avelead from the acquisition date, August 16, 2021
STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
RECONCILIATION OF LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA
(rounded to the nearest thousand dollars)
| Three Months Ended January 31 | Twelve Months Ended January 31 | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Loss from Continuing Operations | $ | (2,182,000 | ) | $ | (4,000 | ) | $ | (11,379,000 | ) | $ | (6,917,000 | ) | ||||
| Interest expense | 230,000 | 129,000 | 749,000 | 236,000 | ||||||||||||
| Income tax benefit | 49,000 | 100,000 | 71,000 | 109,000 | ||||||||||||
| Depreciation and amortization | 1,021,000 | 1,104,000 | 4,233,000 | 3,646,000 | ||||||||||||
| EBITDA | (882,000 | ) | 1,329,000 | (6,326,000 | ) | (2,926,000 | ) | |||||||||
| Share-based compensation expense | 468,000 | 557,000 | 1,680,000 | 2,216,000 | ||||||||||||
| Non-cash valuation adjustments | 117,000 | (2,268,000 | ) | (71,000 | ) | (1,851,000 | ) | |||||||||
| Acquisition-related costs, severance, and transaction-related bonuses | 139,000 | 147,000 | 1,149,000 | 2,856,000 | ||||||||||||
| Forgiveness of PPP Loan and accrued interest | - | - | - | (2,327,000 | ) | |||||||||||
| Other non-recurring operating expenses | (49,000 | ) | (64,000 | ) | (189,000 | ) | (48,000 | ) | ||||||||
| Loss on early extinguishment of debt | - | - | - | 43,000 | ||||||||||||
| Adjusted EBITDA | (207,000 | ) | (299,000 | ) | (3,757,000 | ) | (2,037,000 | ) | ||||||||
